Bolt Biotherapeutics
BOLT
23 hedge funds and large institutions have $2.31M invested in Bolt Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.87% less ownership
Funds ownership: 31.91% → 31.04% (-0.87%)
4% less funds holding
Funds holding: 24 → 23 (-1)
7% less capital invested
Capital invested by funds: $2.49M → $2.31M (-$178K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$220K |
| 2 |
Renaissance Technologies
New York
|
+$100K |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$11.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.9K |
| 5 |
SC
Shay Capital
New York
|
+$2.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$172K |
| 2 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$114K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$45.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.5K |
BOLT Hedge Fund Activity: Q2 2026 in Review
23 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2026, worth a combined $2.31M — down 7.2% from $2.49M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BOLT and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, adding an estimated $220K. The largest seller was Pivotal bioVenture Partners Investment Advisor, exiting entirely with an estimated $172K sold.
- 23 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2026, down from 24 in Q1 2026.
- Funds reported $2.31M of Bolt Biotherapeutics stock for Q2 2026, down 7.2% quarter-over-quarter.
- 2 funds opened new Bolt Biotherapeutics positions in Q2 2026 and 3 closed out, a net change of -1 holder.
- The largest Bolt Biotherapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $220K added.
- The largest Bolt Biotherapeutics seller in Q2 2026 was Pivotal bioVenture Partners Investment Advisor, an estimated $172K sold.
Based on aggregated 13F filings for Q2 2026.